A Review on Pharmacological Advancement of Ellagic Acid

Background: In recent years, ellagic acid has emerged as a focal point in pharmacological research, showcasing promising developments and potential therapeutic applications as a competitive inhibitor of Src homology phosphotyrosyl phosphatase 2 for the treatment of cancer, as a shielding impact that stimulates sirtuin 6 (SIRT 6), against nephrotoxicity induced by cisplatin, as adjuvant treatment in sickle cell anemia, as antiaging and to avoid mild cognitive impairment. Purpose: This review provides a concise overview of the latest advancements in ellagic acid research, highlighting novel pharmacological findings and emerging trends. Methodology: A comprehensive search of relevant literature was conducted to gather information on the pharmacological properties and therapeutic applications of ellagic acid. Studies investigating its antioxidant properties, anti-inflammatory effects, molecular interactions, and therapeutic implications were included in the analysis. Results: The review summarizes the multifaceted pharmacological landscape of ellagic acid, encompassing its antioxidant properties, anti-inflammatory effects, and potential therapeutic applications. It sheds light on its evolving role in modern medicine and underscores its significance as a promising avenue for future pharmaceutical exploration. Conclusion: The recent strides in ellagic acid development highlight its potential as a valuable therapeutic agent in various health conditions. Further research into its molecular interactions and clinical applications is warranted to fully harness its therapeutic potential and improve patient outcomes.